Skip to content

PTSD: all studies

Page 193 of 211: studies 1,921 to 1,930 of 2,101, newest first. Back to the PTSD overview

Research

Potential Psychiatric Uses for MDMA

Clinical Pharmacology & Therapeutics November 10, 2016 Bb Yazar‐klosinski, Mc Mithoefer 81 citations

Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administered in a model of medication‐assisted psychotherapy, differing from trials involving daily drug...

DOI: 10.1002/cpt.565 (opens in new tab) MDMA-Assisted Psychotherapy PTSD Treatment Mental health innovation Regulatory pathways

Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.

Naunyn-Schmiedeberg's Archives of Pharmacology September 20, 2016 Jakob A. Shimshoni, Ilan Winkler, Ezekiel Golan et al. 23 citations

3,4-Methylenedioxy-N-methylamphetamine (MDMA) has been shown to be effective in the treatment of post-traumatic stress disorder (PTSD) in numerous clinical trials. In the present study, we have characterized the neurochemical binding profiles of three MDMA-benzofuran analogues (1-(benzofuran-5-yl)-propan-2-amine, 5-APB; 1-(benzofuran-6-yl)-N-methylpropan-2-amine, 6-MAPB;...

DOI: 10.1007/s00210-016-1297-4 (opens in new tab) Novel compounds Indole analogues Benzofuran analogues New compounds +29

The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux

Biochemical Pharmacology September 13, 2016 Natalie R Sealover, Bruce Felts, Charles P. Kuntz et al.

The substituted amphetamine, 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy), is a widely used drug of abuse that induces non-exocytotic release of serotonin, dopamine, and norepinephrine through their cognate transporters as well as blocking the reuptake of neurotransmitter by the same transporters. The resulting dramatic increase in volume transmission and signal duration of...

A review of the relation between dissociation, memory, executive functioning and social cognition in military members and civilians with neuropsychiatric conditions.

Neuropsychologia September 2016 Margaret C Mckinnon, Jenna E Boyd, Paul Frewen et al.

Dissociative experiences, involving altered states of consciousness, have long been understood as a consequence or response to traumatic experiences, where a reduced level of consciousness may aid in survival during and after a traumatic event. Indeed, the dissociative subtype of post-traumatic stress disorder (PTSD-DS) was added recently to the Diagnostic and Statistical Manual of Mental...

DOI: 10.1016/j.neuropsychologia.2016.07.017 (opens in new tab) Full text (opens in new tab) Dissociation Executive functioning Intrinsic networks Memory +2

Psychedelics, Spirituality, and Transformation

Tikkun July 6, 2016 Phil Wolfson 3 citations

Research Article| January 01 2011 Psychedelics, Spirituality, and Transformation Phil Wolfson Phil Wolfson Author InformationPhil Wolfson, MD, is a practicing psychiatrist/psychotherapist in the Bay Area. He is the author of the forthcoming Noe—A Father/Son Song of Love, Life, Sickness and Death. Search for other works by this author on: This Site Google Tikkun (2011) 26 (1): 10–88....

Randomized-controlled trial of mindfulness-based cancer recovery versus supportive expressive group therapy among distressed breast cancer survivors (MINDSET): long-term follow-up results.

Psycho-Oncology July 2016 Linda E. Carlson, Rie Tamagawa, Joanne Stephen et al.

Mindfulness-based cancer recovery (MBCR) and supportive expressive group therapy (SET) are two well-validated psychosocial interventions, but they have not been directly compared, and little is known about long-term outcomes. This comparative effectiveness study measured the effects of these two interventions immediately following the groups and for 1 year thereafter in distressed breast cancer...

DOI: 10.1002/pon.4150 (opens in new tab) Full text (opens in new tab) Meditation Breast cancer Clinical trial Psycho-oncology +1

Effects of 3,4-Methylenedioxymethamphetamine on Patient Utterances in a Psychotherapeutic Setting.

The Journal of Nervous and Mental Disease July 2016 Vicka Rael Corey, Vincent D Pisano, John H. Halpern

3,4-Methylenedioxymethamphetamine (MDMA) administered as an adjunct to talk therapy influences patient speech content and increases improvement in treatment-resistant posttraumatic stress disorder (PTSD). Data came from the recordings of Mithoefer et al. (2011). In the third therapeutic session studied, patients were assigned, double blind, to an MDMA or a placebo group. Condition-blind scorers...

Pathological spirit possession as a cultural interpretation of trauma-related symptoms.

Psychological Trauma: Theory, Research, Practice and Policy July 1, 2016 Tobias Hecker, Eva Barnewitz, Hakon Stenmark et al. 27 citations

Spirit possession is a phenomenon frequently occurring in war-torn countries. It has been shown to be an idiom of distress entailing dissociative symptoms. However, its association with trauma exposure and trauma-related disorders remains unclear. This study aimed to explore subjective disease models and the relationship between pathological spirit possession and trauma-related disorders in the...

Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor

Journal of Psychosocial Nursing and Mental Health Services June 30, 2016 Robert H Howland 22 citations

Antidepressant, atypical antipsychotic, and hallucinogen drugs mediate their actions in part by interactions with the serotonin-2A (5HT2A) receptor. Serotonergic hallucinogen drugs, such as psilocybin, bind most potently as agonists at the 5HT2A receptor, producing profound changes in perception, mood, and cognition. Some of these drugs have been or are currently being investigated in small...

Ketamine for treatment-resistant depression: recent developments and clinical applications.

Evidence-Based Mental Health May 2016 Jaclyn Schwartz, James W. Murrough, Dan V. Iosifescu

Approximately one-third of patients with major depressive disorder (MDD) do not respond to existing antidepressants, and those who do generally take weeks to months to achieve a significant effect. There is a clear unmet need for rapidly acting and more efficacious treatments. We will review recent developments in the study of ketamine, an old anaesthetic agent which has shown significant...